1
|
Torres-Fuentes C, Chevre R, Ortega-Gomez A. Editorial: Diets and eating patterns: effects on the immune system and its regulation. Front Nutr 2023; 10:1305736. [PMID: 38024338 PMCID: PMC10666622 DOI: 10.3389/fnut.2023.1305736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2023] [Accepted: 10/25/2023] [Indexed: 12/01/2023] Open
Affiliation(s)
- Cristina Torres-Fuentes
- Nutrigenomics Research Group, Department of Biochemistry and Biotechnology, Universitat Rovira i Virgili, Tarragona, Spain
| | - Raphael Chevre
- Institute of Experimental Pathology (ExPat), Center of Molecular Biology of Inflammation (ZMBE), University of Münster, Münster, Germany
| | - Almudena Ortega-Gomez
- Department of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, Málaga, Spain
- Biomedical Research Institute of Malaga and Platform in Nanomedicine (IBIMA-BIONAND Platform), Málaga, Spain
- Centro de Investigación Biomédica en Red in Physiopathology of Obesity and Nutrition (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
2
|
Gatsiou A, Tual-Chalot S, Napoli M, Ortega-Gomez A, Regen T, Badolia R, Cesarini V, Garcia-Gonzalez C, Chevre R, Ciliberti G, Silvestre-Roig C, Martini M, Hoffmann J, Hamouche R, Visker JR, Diakos N, Wietelmann A, Silvestris DA, Georgiopoulos G, Moshfegh A, Schneider A, Chen W, Guenther S, Backs J, Kwak S, Selzman CH, Stamatelopoulos K, Rose-John S, Trautwein C, Spyridopoulos I, Braun T, Waisman A, Gallo A, Drakos SG, Dimmeler S, Sperandio M, Soehnlein O, Stellos K. The RNA editor ADAR2 promotes immune cell trafficking by enhancing endothelial responses to interleukin-6 during sterile inflammation. Immunity 2023; 56:979-997.e11. [PMID: 37100060 DOI: 10.1016/j.immuni.2023.03.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2022] [Revised: 01/02/2023] [Accepted: 03/30/2023] [Indexed: 04/28/2023]
Abstract
Immune cell trafficking constitutes a fundamental component of immunological response to tissue injury, but the contribution of intrinsic RNA nucleotide modifications to this response remains elusive. We report that RNA editor ADAR2 exerts a tissue- and stress-specific regulation of endothelial responses to interleukin-6 (IL-6), which tightly controls leukocyte trafficking in IL-6-inflamed and ischemic tissues. Genetic ablation of ADAR2 from vascular endothelial cells diminished myeloid cell rolling and adhesion on vascular walls and reduced immune cell infiltration within ischemic tissues. ADAR2 was required in the endothelium for the expression of the IL-6 receptor subunit, IL-6 signal transducer (IL6ST; gp130), and subsequently, for IL-6 trans-signaling responses. ADAR2-induced adenosine-to-inosine RNA editing suppressed the Drosha-dependent primary microRNA processing, thereby overwriting the default endothelial transcriptional program to safeguard gp130 expression. This work demonstrates a role for ADAR2 epitranscriptional activity as a checkpoint in IL-6 trans-signaling and immune cell trafficking to sites of tissue injury.
Collapse
Affiliation(s)
- Aikaterini Gatsiou
- Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK; RNA Metabolism and Vascular Inflammation Laboratory, Institute of Cardiovascular Regeneration and Department of Cardiology, JW Goethe University Frankfurt, Frankfurt am Main, Germany.
| | - Simon Tual-Chalot
- Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
| | - Matteo Napoli
- Institute for Cardiovascular Physiology and Pathophysiology, Walter Brendel Center for Experimental Medicine Biomedical Center (BMC), Ludwig-Maximilians-Universität München, Munich, Germany
| | - Almudena Ortega-Gomez
- Institute for Cardiovascular Prevention (IPEK), LMU Munich Hospital, Munich, Germany
| | - Tommy Regen
- Institute for Molecular Medicine, University Medical Center of the Johannes Gutenberg University of Mainz, Mainz, Germany
| | - Rachit Badolia
- Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI), University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Valeriana Cesarini
- Department of Pediatric Hematology/Oncology and Cellular and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | | | - Raphael Chevre
- Institute for Cardiovascular Prevention (IPEK), LMU Munich Hospital, Munich, Germany; Institute for Experimental Pathology (ExPat), Center for Molecular Biology of Inflammation, WWU Muenster, Muenster, Germany
| | - Giorgia Ciliberti
- Department of Cardiovascular Research, European Center for Angioscience (ECAS), Heidelberg University, Mannheim, Germany
| | - Carlos Silvestre-Roig
- Institute for Cardiovascular Prevention (IPEK), LMU Munich Hospital, Munich, Germany; Institute for Experimental Pathology (ExPat), Center for Molecular Biology of Inflammation, WWU Muenster, Muenster, Germany
| | - Maurizio Martini
- Fondazione Policlinico Universitario "A. Gemelli," IRCCS, UOC Anatomia Patologica, Rome, Italy; Istituto di Anatomia Patologica, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Jedrzej Hoffmann
- Department of Cardiology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Rana Hamouche
- Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI), University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Joseph R Visker
- Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI), University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Nikolaos Diakos
- Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI), University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Astrid Wietelmann
- Max-Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
| | - Domenico Alessandro Silvestris
- Department of Pediatric Hematology/Oncology and Cellular and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - Georgios Georgiopoulos
- Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece; Translational Research Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
| | - Ali Moshfegh
- Kancera AB, Stockholm, Sweden; Department of Oncology and Pathology at Karolinska Institutet, Stockholm, Sweden
| | - Andre Schneider
- Max-Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
| | - Wei Chen
- Department of Biology, Southern University of Science and Technology, Shenzhen, Guangdong, China; Medi-X Institute, SUSTech Academy for Advanced Interdisciplinary Studies, Southern University of Science and Technology, Shenzhen, Guangdong, China
| | - Stefan Guenther
- Max-Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
| | - Johannes Backs
- Institute of Experimental Cardiology, University Hospital Heidelberg, Heidelberg, Germany; German Centre for Cardiovascular Research (Deutsches Zentrum für Herz-Kreislauf-Forschung, DZHK), Heidelberg/Mannheim Partner Site, Heidelberg and Mannheim, Germany
| | - Shin Kwak
- Department of Molecular Neuropathogenesis, Tokyo Medical University, Tokyo, Japan
| | - Craig H Selzman
- Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI), University of Utah School of Medicine, Salt Lake City, UT, USA; Division of Cardiothoracic Surgery, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Kimon Stamatelopoulos
- Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece; Translational Research Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
| | - Stefan Rose-John
- Institute of Biochemistry, Christian-Albrechts-University Kiel, Kiel, Germany
| | - Christian Trautwein
- Department of Internal Medicine III, University Hospital RWTH Aachen, Aachen, Germany
| | - Ioakim Spyridopoulos
- Translational Research Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK; Department of Cardiology, Freeman Hospital, Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK
| | - Thomas Braun
- Max-Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
| | - Ari Waisman
- Institute for Molecular Medicine, University Medical Center of the Johannes Gutenberg University of Mainz, Mainz, Germany
| | - Angela Gallo
- Department of Pediatric Hematology/Oncology and Cellular and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - Stavros G Drakos
- Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI), University of Utah School of Medicine, Salt Lake City, UT, USA; Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Stefanie Dimmeler
- Institute of Cardiovascular Regeneration, Center of Molecular Medicine, JW Goethe University Frankfurt, Frankfurt am Main, Germany; German Centre for Cardiovascular Research (Deutsches Zentrum für Herz-Kreislauf-Forschung, DZHK), Frankfurt Partner Site, Germany
| | - Markus Sperandio
- Institute for Cardiovascular Physiology and Pathophysiology, Walter Brendel Center for Experimental Medicine Biomedical Center (BMC), Ludwig-Maximilians-Universität München, Munich, Germany; German Centre for Cardiovascular Research (Deutsches Zentrum für Herz-Kreislauf-Forschung, DZHK), Munich Heart Alliance Partner Site, Munich, Germany
| | - Oliver Soehnlein
- Institute for Cardiovascular Prevention (IPEK), LMU Munich Hospital, Munich, Germany; Institute for Experimental Pathology (ExPat), Center for Molecular Biology of Inflammation, WWU Muenster, Muenster, Germany; German Centre for Cardiovascular Research (Deutsches Zentrum für Herz-Kreislauf-Forschung, DZHK), Munich Heart Alliance Partner Site, Munich, Germany; Department of Physiology and Pharmacology (FyFa), Karolinska Institutet, Stockholm, Sweden
| | - Konstantinos Stellos
- Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK; RNA Metabolism and Vascular Inflammation Laboratory, Institute of Cardiovascular Regeneration and Department of Cardiology, JW Goethe University Frankfurt, Frankfurt am Main, Germany; Department of Cardiovascular Research, European Center for Angioscience (ECAS), Heidelberg University, Mannheim, Germany; German Centre for Cardiovascular Research (Deutsches Zentrum für Herz-Kreislauf-Forschung, DZHK), Heidelberg/Mannheim Partner Site, Heidelberg and Mannheim, Germany; Cardio-Pulmonary Institute (CPI), Frankfurt am Main, Germany.
| |
Collapse
|
3
|
Ortega-Gomez A, Lopez S, Varela LM, Jaramillo S, Muriana FJ, Abia R. New evidence for dietary fatty acids in the neutrophil traffic between the bone marrow and the peripheral blood. Food Chemistry: Molecular Sciences 2022; 5:100133. [PMID: 36111060 PMCID: PMC9467871 DOI: 10.1016/j.fochms.2022.100133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/08/2022] [Revised: 09/02/2022] [Accepted: 09/03/2022] [Indexed: 11/11/2022]
Abstract
SFAs but not MUFAs boosted neutrophils both in bone marrow and blood. SFAs were strong inducers of bone marrow neutrophil apoptosis and inflammation. CXCL2-CXCR2 axis engaged in fatty-acid-mediated navigation of neutrophils. Fatty-acid-dependent neutrophilia occurred in a postprandial model.
Chronic administration of a high-fat diet in mice has been established to influence the generation and trafficking of immune cells such as neutrophils in the bone marrow, the dysregulation of which may contribute to a wide range of diseases. However, no studies have tested the hypothesis that a short-term, high-fat diet could early modulate the neutrophil release from bone marrow at fasting and at postprandial in response to a high-fat meal challenge, and that the predominant type of fatty acids in dietary fats could play a role in both context conditions. Based on these premises, we aimed to establish the effects of different fats [butter, enriched in saturated fatty acids (SFAs), olive oil, enriched in monounsaturated fatty acids (MUFAs), and olive oil supplemented with eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids] on neutrophil navigation from bone marrow to blood in mice. The analysis of cellular models for mechanistic understanding and of postprandial blood samples from healthy volunteers for translational purposes was assessed. The results revealed a powerful effect of dietary SFAs in promotion the neutrophil traffic from bone marrow to blood via the CXCL2-CXCR2 axis. Dietary SFAs, but not MUFAs or EPA and DHA, were also associated with increased neutrophil apoptosis and bone marrow inflammation. Similar dietary fatty-acid-induced postprandial neutrophilia was observed in otherwise healthy humans. Therefore, dietary MUFAs might preserve bone marrow health and proper migration of bone marrow neutrophils early in the course of high-fat diets even after the intake of high-fat meals.
Collapse
|
4
|
Motahari-Rad H, Subiri A, Soler R, Ocaña L, Alcaide J, Rodríguez-Capitan J, Buil V, el Azzouzi H, Ortega-Gomez A, Bernal-Lopez R, Insenser M, Tinahones FJ, Murri M. The Effect of Sex and Obesity on the Gene Expression of Lipid Flippases in Adipose Tissue. J Clin Med 2022; 11:jcm11133878. [PMID: 35807162 PMCID: PMC9267438 DOI: 10.3390/jcm11133878] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2022] [Revised: 06/25/2022] [Accepted: 06/28/2022] [Indexed: 01/25/2023] Open
Abstract
Molecular mechanisms behind obesity and sex-related effects in adipose tissue remain elusive. During adipocyte expansion, adipocytes undergo drastic remodelling of lipid membrane compositions. Lipid flippases catalyse phospholipid translocation from exoplasmic to the cytoplasmic leaflet of membranes. The present study aimed to analyse the effect of sex, obesity, and their interactions on the gene expression of two lipid flippases—ATP8A1 and ATP8B1—and their possible microRNA (miR) modulators in visceral adipose tissue (VAT). In total, 12 normal-weight subjects (5 premenopausal women and 7 men) and 13 morbidly obese patients (7 premenopausal women and 6 men) were submitted to surgery, and VAT samples were obtained. Gene expression levels of ATP8A1, ATP8B1, miR-548b-5p, and miR-4643 were measured in VAT. Our results showed a marked influence of obesity on VAT ATP8A1 and ATP8B1, although the effects of obesity were stronger in men for ATP8A1. Both genes positively correlated with obesity and metabolic markers. Furthermore, ATP8B1 was positively associated with miR-548b-5p and negatively associated with miR-4643. Both miRs were also affected by sex. Thus, lipid flippases are altered by obesity in VAT in a sex-specific manner. Our study provides a better understanding of the sex-specific molecular mechanisms underlying obesity, which may contribute to the development of sex-based precision medicine.
Collapse
Affiliation(s)
- Hanieh Motahari-Rad
- Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran 14117-13116, Iran;
- Clinical Management Unit (UGC) of Endocrinology and Nutrition, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Clínico Virgen de la Victoria, 29010 Málaga, Spain; (A.S.); (J.A.); (A.O.-G.); (F.J.T.)
| | - Alba Subiri
- Clinical Management Unit (UGC) of Endocrinology and Nutrition, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Clínico Virgen de la Victoria, 29010 Málaga, Spain; (A.S.); (J.A.); (A.O.-G.); (F.J.T.)
- CIBER Fisiopatología de la Obesidad y Nutrición (CIlBEROBN), Instituto de Salud Carlos III, 29010 Málaga, Spain;
| | - Rocio Soler
- Clinical Management Unit (UGC) of General and Digestive Surgery, Virgen de la Victoria University Hospital, 29010 Málaga, Spain; (R.S.); (L.O.)
| | - Luis Ocaña
- Clinical Management Unit (UGC) of General and Digestive Surgery, Virgen de la Victoria University Hospital, 29010 Málaga, Spain; (R.S.); (L.O.)
| | - Juan Alcaide
- Clinical Management Unit (UGC) of Endocrinology and Nutrition, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Clínico Virgen de la Victoria, 29010 Málaga, Spain; (A.S.); (J.A.); (A.O.-G.); (F.J.T.)
- CIBER Fisiopatología de la Obesidad y Nutrición (CIlBEROBN), Instituto de Salud Carlos III, 29010 Málaga, Spain;
| | - Jorge Rodríguez-Capitan
- Clinical Management Unit (UGC) of Heart, Virgen de la Victoria University Hospital, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Universidad de Málaga (UMA), Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), 29010 Málaga, Spain;
- Faculty of Medicine, University of Malaga, 29010 Malaga, Spain;
| | - Veronica Buil
- Faculty of Medicine, University of Malaga, 29010 Malaga, Spain;
| | - Hamid el Azzouzi
- Department of Molecular Genetics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands;
| | - Almudena Ortega-Gomez
- Clinical Management Unit (UGC) of Endocrinology and Nutrition, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Clínico Virgen de la Victoria, 29010 Málaga, Spain; (A.S.); (J.A.); (A.O.-G.); (F.J.T.)
- CIBER Fisiopatología de la Obesidad y Nutrición (CIlBEROBN), Instituto de Salud Carlos III, 29010 Málaga, Spain;
| | - Rosa Bernal-Lopez
- CIBER Fisiopatología de la Obesidad y Nutrición (CIlBEROBN), Instituto de Salud Carlos III, 29010 Málaga, Spain;
- Clinical Management Unit (UGC) of Internal Medicine, IBIMA, Hospital Regional Universitario de Málaga, 29009 Málaga, Spain
| | - Maria Insenser
- Diabetes, Obesity and Human Reproduction Research Group, Department of Endocrinology & Nutrition, Hospital Universitario Ramón y Cajal & Universidad de Alcalá & Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) & Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 28034 Madrid, Spain
- Correspondence: (M.I.); (M.M.)
| | - Francisco J. Tinahones
- Clinical Management Unit (UGC) of Endocrinology and Nutrition, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Clínico Virgen de la Victoria, 29010 Málaga, Spain; (A.S.); (J.A.); (A.O.-G.); (F.J.T.)
- CIBER Fisiopatología de la Obesidad y Nutrición (CIlBEROBN), Instituto de Salud Carlos III, 29010 Málaga, Spain;
- Faculty of Medicine, University of Malaga, 29010 Malaga, Spain;
| | - Mora Murri
- Clinical Management Unit (UGC) of Endocrinology and Nutrition, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Clínico Virgen de la Victoria, 29010 Málaga, Spain; (A.S.); (J.A.); (A.O.-G.); (F.J.T.)
- CIBER Fisiopatología de la Obesidad y Nutrición (CIlBEROBN), Instituto de Salud Carlos III, 29010 Málaga, Spain;
- Correspondence: (M.I.); (M.M.)
| |
Collapse
|
5
|
Maciuszek M, Ortega-Gomez A, Maas SL, Garrido-Mesa J, Ferraro B, Perretti M, Merritt A, Nicolaes GAF, Soehnlein O, Chapman TM. Design, synthesis, and biological evaluation of novel pyrrolidinone small-molecule Formyl peptide receptor 2 agonists. Eur J Med Chem 2021; 226:113805. [PMID: 34536667 DOI: 10.1016/j.ejmech.2021.113805] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2021] [Revised: 08/23/2021] [Accepted: 08/24/2021] [Indexed: 10/20/2022]
Abstract
A series of Formyl peptide receptor 2 small molecule agonists with a pyrrolidinone scaffold, derived from a combination of pharmacophore modelling and docking studies, were designed and synthesized. The GLASS (GPCR-Ligand Association) database was screened using a pharmacophore model. The most promising novel ligand structures were chosen and then tested in cellular assays (calcium mobilization and β-arrestin assays). Amongst the selected ligands, two pyrrolidinone compounds (7 and 8) turned out to be the most active. Moreover compound 7 was able to reduce the number of adherent neutrophils in a human neutrophil static adhesion assay which indicates its anti-inflammatory and proresolving properties. Further exploration and optimization of new ligands showed that heterocyclic rings, e.g. pyrazole directly connected to the pyrrolidinone scaffold, provide good stability and a boost in the agonistic activity. The compounds of most interest (7 and 30) were tested in an ERK phosphorylation assay, demonstrating selectivity towards FPR2 over FPR1. Compound 7 was examined in an in vivo mouse pharmacokinetic study. Compound 7 may be a valuable in vivo tool and help improve understanding of the role of the FPR2 receptor in the resolution of inflammation process.
Collapse
Affiliation(s)
- Monika Maciuszek
- LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, UK; The William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London, UK.
| | - Almudena Ortega-Gomez
- Institute for Cardiovascular Prevention (IPEK), LMU Munich Hospital, Munich, Germany
| | - Sanne L Maas
- Institute for Cardiovascular Prevention (IPEK), LMU Munich Hospital, Munich, Germany
| | - Jose Garrido-Mesa
- The William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London, UK
| | - Bartolo Ferraro
- Institute for Cardiovascular Prevention (IPEK), LMU Munich Hospital, Munich, Germany
| | - Mauro Perretti
- The William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London, UK
| | - Andy Merritt
- LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, UK
| | - Gerry A F Nicolaes
- CARIM - School for Cardiovascular Sciences Department of Biochemistry, Maastricht University, Maastricht, Netherlands
| | - Oliver Soehnlein
- Institute for Cardiovascular Prevention (IPEK), LMU Munich Hospital, Munich, Germany; Department of Physiology and Pharmacology (FyFa), Karolinska Institute, Stockholm, Sweden; Institute for Experimental Pathology (ExPat), Centre for Molecular Biology of Inflammation, University of Münster, Münster, Germany
| | - Timothy M Chapman
- LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, UK
| |
Collapse
|
6
|
Maciuszek M, Ortega-Gomez A, Maas SL, Perretti M, Merritt A, Soehnlein O, Chapman TM. Synthesis and evaluation of novel cyclopentane urea FPR2 agonists and their potential application in the treatment of cardiovascular inflammation. Eur J Med Chem 2021; 214:113194. [PMID: 33548634 DOI: 10.1016/j.ejmech.2021.113194] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2020] [Revised: 01/08/2021] [Accepted: 01/10/2021] [Indexed: 12/11/2022]
Abstract
The discovery of natural specialized pro-resolving mediators and their corresponding receptors, such as formyl peptide receptor 2 (FPR2), indicated that resolution of inflammation (RoI) is an active process which could be harnessed for innovative approaches to tame pathologies with underlying chronic inflammation. In this work, homology modelling, molecular docking and pharmacophore studies were deployed to assist the rationalization of the structure-activity relationships of known FPR2 agonists. The developed pharmacophore hypothesis was then used in parallel with the homology model for the design of novel ligand structures and in virtual screening. In the first round of optimization compound 8, with a cyclopentane core, was chosen as the most promising agonist (β-arrestin recruitment EC50 = 20 nM and calcium mobilization EC50 = 740 nM). In a human neutrophil static adhesion assay, compound 8 decreased the number of adherent neutrophils in a concentration dependent manner. Further investigation led to the more rigid cycloleucines (compound 22 and 24) with improved ADME profiles and maintaining FPR2 activity. Overall, we identified novel cyclopentane urea FPR2 agonists with promising ADMET profiles and the ability to suppress the inflammatory process by inhibiting the neutrophil adhesion cascade, which indicates their anti-inflammatory and pro-resolving properties.
Collapse
Affiliation(s)
- Monika Maciuszek
- LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, UK; The William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London, UK.
| | - Almudena Ortega-Gomez
- Institute for Cardiovascular Prevention (IPEK), LMU Munich Hospital, Munich, Germany
| | - Sanne L Maas
- Institute for Cardiovascular Prevention (IPEK), LMU Munich Hospital, Munich, Germany
| | - Mauro Perretti
- The William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London, UK
| | - Andy Merritt
- LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, UK
| | - Oliver Soehnlein
- Institute for Cardiovascular Prevention (IPEK), LMU Munich Hospital, Munich, Germany; Department of Physiology and Pharmacology (FyFa), Karolinska Institute, Stockholm, Sweden; German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance (MHA), Munich, Germany
| | - Timothy M Chapman
- LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, UK
| |
Collapse
|
7
|
Ortega-Gomez A, Soehnlein O. Lack of Proteinase 3 Stabilizes Advanced Atherosclerotic Lesions. Thromb Haemost 2020; 120:994-997. [PMID: 32403136 DOI: 10.1055/s-0040-1710316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- Almudena Ortega-Gomez
- Institute for Cardiovascular Prevention, LMU Munich, Munich, Germany.,DZHK, Partner site Munich Heart Alliance, Munich, Germany
| | - Oliver Soehnlein
- Institute for Cardiovascular Prevention, LMU Munich, Munich, Germany.,DZHK, Partner site Munich Heart Alliance, Munich, Germany.,Department of Physiology and Pharmacology (FyFa), Karolinska Institutet, Stockholm, Sweden
| |
Collapse
|
8
|
Ferraro B, Leoni G, Hinkel R, Ormanns S, Paulin N, Ortega-Gomez A, Viola JR, de Jong R, Bongiovanni D, Bozoglu T, Maas SL, D'Amico M, Kessler T, Zeller T, Hristov M, Reutelingsperger C, Sager HB, Döring Y, Nahrendorf M, Kupatt C, Soehnlein O. Pro-Angiogenic Macrophage Phenotype to Promote Myocardial Repair. J Am Coll Cardiol 2020; 73:2990-3002. [PMID: 31196457 DOI: 10.1016/j.jacc.2019.03.503] [Citation(s) in RCA: 102] [Impact Index Per Article: 25.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/04/2018] [Revised: 03/12/2019] [Accepted: 03/19/2019] [Indexed: 11/25/2022]
Abstract
BACKGROUND Heart failure following myocardial infarction (MI) remains one of the major causes of death worldwide, and its treatment is a crucial challenge of cardiovascular medicine. An attractive therapeutic strategy is to stimulate endogenous mechanisms of myocardial regeneration. OBJECTIVES This study evaluates the potential therapeutic treatment with annexin A1 (AnxA1) to induce cardiac repair after MI. METHODS AnxA1 knockout (AnxA1-/-) and wild-type mice underwent MI induced by ligation of the left anterior descending coronary artery. Cardiac functionality was assessed by longitudinal echocardiographic measurements. Histological, fluorescence-activated cell sorting, dot blot analysis, and in vitro/ex vivo studies were used to assess the myocardial neovascularization, macrophage content, and activity in response to AnxA1. RESULTS AnxA1-/- mice showed a reduced cardiac functionality and an expansion of proinflammatory macrophages in the ischemic area. Cardiac macrophages from AnxA1-/- mice exhibited a dramatically reduced ability to release the proangiogenic mediator vascular endothelial growth factor (VEGF)-A. However, AnxA1 treatment enhanced VEGF-A release from cardiac macrophages, and its delivery in vivo markedly improved cardiac performance. The positive effect of AnxA1 treatment on cardiac performance was abolished in wild-type mice transplanted with bone marrow derived from Cx3cr1creERT2Vegfflox/flox or in mice depleted of macrophages. Similarly, cardioprotective effects of AnxA1 were obtained in pigs in which full-length AnxA1 was overexpressed by use of a cardiotropic adeno-associated virus. CONCLUSIONS AnxA1 has a direct action on cardiac macrophage polarization toward a pro-angiogenic, reparative phenotype. AnxA1 stimulated cardiac macrophages to release high amounts of VEGF-A, thus inducing neovascularization and cardiac repair.
Collapse
Affiliation(s)
- Bartolo Ferraro
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität Munich, Munich, Germany; Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), partner site Munich Heart Alliance, Munich, Germany
| | - Giovanna Leoni
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität Munich, Munich, Germany; Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), partner site Munich Heart Alliance, Munich, Germany
| | - Rabea Hinkel
- Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), partner site Munich Heart Alliance, Munich, Germany; Medizinische Klinik I, TU Munich, Germany; Deutsches Primatenzentrum GmbH, Leibniz-Institut für Primatenforschung, Department of Laboratory Animal Science, Göttingen, Germany
| | - Steffen Ormanns
- Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Nicole Paulin
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität Munich, Munich, Germany; Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), partner site Munich Heart Alliance, Munich, Germany
| | - Almudena Ortega-Gomez
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität Munich, Munich, Germany; Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), partner site Munich Heart Alliance, Munich, Germany
| | - Joana R Viola
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität Munich, Munich, Germany; Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), partner site Munich Heart Alliance, Munich, Germany
| | - Renske de Jong
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität Munich, Munich, Germany
| | - Dario Bongiovanni
- Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), partner site Munich Heart Alliance, Munich, Germany; Medizinische Klinik I, TU Munich, Germany
| | | | - Sanne L Maas
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität Munich, Munich, Germany; Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), partner site Munich Heart Alliance, Munich, Germany
| | - Michele D'Amico
- Department of Experimental Medicine, University of Campania, Campania, Italy
| | - Thorsten Kessler
- Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), partner site Munich Heart Alliance, Munich, Germany; Department of Cardiology, German Heart Center Munich, Munich, Germany
| | - Tanja Zeller
- DZHK, Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany; Clinic for Cardiology, University Heart Center, Hamburg, Germany
| | - Michael Hristov
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität Munich, Munich, Germany
| | - Chris Reutelingsperger
- Department of Biochemistry, Cardiovascular Research Institute Maastricht, University Maastricht, Maastricht, the Netherlands
| | - Hendrik B Sager
- Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), partner site Munich Heart Alliance, Munich, Germany; Department of Cardiology, German Heart Center Munich, Munich, Germany
| | - Yvonne Döring
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität Munich, Munich, Germany; Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), partner site Munich Heart Alliance, Munich, Germany
| | - Matthias Nahrendorf
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - Christian Kupatt
- Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), partner site Munich Heart Alliance, Munich, Germany; Medizinische Klinik I, TU Munich, Germany
| | - Oliver Soehnlein
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität Munich, Munich, Germany; Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), partner site Munich Heart Alliance, Munich, Germany; Department of Physiology and Pharmacology (FyFa) and Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
| |
Collapse
|
9
|
Greiffo FR, Viteri-Alvarez V, Frankenberger M, Dietel D, Ortega-Gomez A, Lee JS, Hilgendorff A, Behr J, Soehnlein O, Eickelberg O, Fernandez IE. CX3CR1-fractalkine axis drives kinetic changes of monocytes in fibrotic interstitial lung diseases. Eur Respir J 2020; 55:13993003.00460-2019. [PMID: 31744836 DOI: 10.1183/13993003.00460-2019] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2018] [Accepted: 10/31/2019] [Indexed: 12/21/2022]
Abstract
Circulating immune cell populations have been shown to contribute to interstitial lung disease (ILD). In this study, we analysed circulating and lung resident monocyte populations, and assessed their phenotype and recruitment from the blood to the lung in ILD. Flow cytometry analysis of blood samples for quantifying circulating monocytes was performed in 105 subjects: 83 with ILD (n=36, n=28 and n=19 for nonspecific interstitial pneumonia, hypersensitivity pneumonitis and connective-tissue disease-associated ILD, respectively), as well as 22 controls. Monocyte localisation and abundance were assessed using immunofluorescence and flow cytometry of lung tissue. Monocyte populations were cultured either alone or with endothelial cells to assess fractalkine-dependent transmigration pattern. We show that circulating classical monocytes (CM) were increased in ILD compared with controls, while nonclassical monocytes (NCM) were decreased. CM abundance correlated inversely with lung function, while NCM abundance correlated positively. Both CCL2 and CX3CL1 concentrations were increased in plasma and lungs of ILD patients. Fractalkine co-localised with ciliated bronchial epithelial cells, thereby creating a chemoattractant gradient towards the lung. Fractalkine enhanced endothelial transmigration of NCM in ILD samples only. Immunofluorescence, as well as flow cytometry, showed an increased presence of NCM in fibrotic niches in ILD lungs. Moreover, NCM in the ILD lungs expressed increased CX3CR1, M2-like and phagocytic markers. Taken together, our data support that in ILD, fractalkine drives the migration of CX3CR1+ NCM to the lungs, thereby perpetuating the local fibrotic process.
Collapse
Affiliation(s)
- Flavia R Greiffo
- Comprehensive Pneumology Center, Ludwig-Maximilians University (LMU), University Hospital Grosshadern, and Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Valeria Viteri-Alvarez
- Comprehensive Pneumology Center, Ludwig-Maximilians University (LMU), University Hospital Grosshadern, and Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Marion Frankenberger
- Comprehensive Pneumology Center, Ludwig-Maximilians University (LMU), University Hospital Grosshadern, and Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Daniela Dietel
- Comprehensive Pneumology Center, Ludwig-Maximilians University (LMU), University Hospital Grosshadern, and Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Almudena Ortega-Gomez
- Institute for Cardiovascular Prevention, Ludwig-Maximilians University (LMU), Munich, Germany
| | - Joyce S Lee
- Division of Pulmonary Sciences and Critical Care Medicine, Dept of Medicine, University of Colorado - Anschutz Medical Campus, Aurora, CO, USA
| | - Anne Hilgendorff
- Comprehensive Pneumology Center, Ludwig-Maximilians University (LMU), University Hospital Grosshadern, and Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany.,Dept of Neonatalogy, Perinatal Center Grosshadern Ludwig-Maximilians University, Munich, Germany.,Center for Comprehensive Developmental Care, Dr von Haunersches Children's Hospital University, Hospital Ludwig-Maximilians University, Munich, Germany.,CPC-M bioArchive, Helmholtz Zentrum München, Comprehensive Pneumology Center (CPC), Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Jürgen Behr
- Asklepios Fachkliniken München-Gauting, Munich, Germany.,Comprehensive Pneumology Center, Medizinische Klinik und Poliklinik V, Klinikum der Ludwig-Maximilians Universität (LMU), Member of the German Center of Lung Research (DZL), Munich, Germany
| | - Oliver Soehnlein
- Institute for Cardiovascular Prevention, Ludwig-Maximilians University (LMU), Munich, Germany.,Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), partner site Munich Heart Alliance, Munich, Germany.,Dept of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden
| | - Oliver Eickelberg
- Comprehensive Pneumology Center, Ludwig-Maximilians University (LMU), University Hospital Grosshadern, and Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany.,Division of Pulmonary Sciences and Critical Care Medicine, Dept of Medicine, University of Colorado - Anschutz Medical Campus, Aurora, CO, USA.,These authors contributed equally
| | - Isis E Fernandez
- Comprehensive Pneumology Center, Ludwig-Maximilians University (LMU), University Hospital Grosshadern, and Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany .,CPC-M bioArchive, Helmholtz Zentrum München, Comprehensive Pneumology Center (CPC), Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany.,These authors contributed equally
| |
Collapse
|
10
|
Gatsiou A, Tual-Chalot S, Bonini F, Cesarini V, Ortega-Gomez A, Schook K, Hoffmann J, Kwak S, Selzman CH, Martini M, Dimmeler S, Gallo A, Drakos S, Soehnlein O, Stellos K. 1438MicroRNA editing is integral for interleukin-6 trans-signalling and leukocyte trafficking to ischemic tissues. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0073] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background/Aim
Adenosine to inosine RNA editing is an essential post-transcriptional RNA modification catalysed by adenosine deaminase acting on RNA-1 and -2 (ADAR1; ADAR2). Endothelial cells (ECs) attract and guide leukocytes to sites of ischemic tissue injury. Here we studied the role of RNA editing in ischemic disease.
Methods
Primary human and murine vascular endothelial cell cultures were used to assess the EC responses to interleukin-6 (IL-6) or ischemia. For the animal studies, the effect of ADAR2 in acute and chronic ischemic disease was evaluated in cremaster muscle microcirculation by intravital microscopy, in peritoneal cavity after sterile peritonitis and in gastrocnemius muscle after hind-limb ischemia by 8-colour flow cytometry and immunohistochemistry (IHC) studies of Adar2−/−/tg as well as of i(nducible)EC-ADAR2 knockout (KO) mice. For the mechanistic studies, deep RNA sequencing, qRT-PCR, western blot, confocal microscopy, target-specific microRNA (miRNA) editing studies, RNA-immunoprecipitation, miRNA/plasmid silencing/overexpression and luciferase reporter assays were used among others. For human studies, ischemic tissues derived from patients with acute or chronic ischemic heart disease were processed.
Results
ADAR2, but not ADAR1, expression is induced by >2-fold in hypoxic ECs and in ischemic vascular ECs in mice and humans. Unbiased gene ontology analysis of the EC transcriptome indicated that ADAR2 controls inflammatory responses and predominantly the expression of interleukin-6-signal transducer (IL6ST), the co-receptor of IL-6. Subsequently, ADAR2 controls IL-6 trans-signalling in ECs as documented by the STAT3 phosphorylation and expression of the downstream leukocyte adhesion molecules, E-selectin and VCAM-1. IL-6-inflamed cremaster muscles showed that rolling and adhesion of leukocyte subsets to vascular wall were severely impaired in Adar2−/−/tg mice. Leukocyte transmigration was also diminished by >2-fold in Adar2−/−/tg and in iEC-ADAR2 KO mice in response to IL-6 or ischemia. Similar results were obtained for leukocyte rolling, adhesion and infiltration after acute (4h) and chronic (3d; 21d) ischemia from iEC-ADAR2 KO mice and human ischemic muscle tissues. Next we studied how ADAR2 controls IL6ST expression. ADAR2-deficient vascular EC miRNAome revealed the upregulation of a conserved group of miRNAs targeting the IL6ST mRNA including miR-199a-5p and miR-335-3p. At a single-nucleotide level, ADAR2-induced RNA editing of the stem loops of the primary miR-199a1/2 and miR-335 directly disrupted Drosha recruitment to both and thus inhibited their maturation process. Accordingly, rescue experiments using miRNA-inhibitors restored IL6ST levels after ADAR2 deficiency.
Conclusion
Taking together, inhibition of the microRNA maturation process by ADAR2-mediated RNA editing is integral for IL-6 trans-signalling in vascular endothelium and subsequent leukocyte trafficking to ischemic tissues in mice and humans.
Collapse
Affiliation(s)
- A Gatsiou
- Newcastle University, Newcastle upon Tyne, United Kingdom
| | - S Tual-Chalot
- Newcastle University, Newcastle upon Tyne, United Kingdom
| | - F Bonini
- Wolfgang Goethe University, Frankfurt am Main, Germany
| | - V Cesarini
- Bambino Gesu Children's Hospital, Rome, Italy
| | - A Ortega-Gomez
- Institute for Cardiovascular Prevention (IPEK), Munich, Germany
| | - K Schook
- Newcastle University, Newcastle upon Tyne, United Kingdom
| | - J Hoffmann
- Wolfgang Goethe University, Frankfurt am Main, Germany
| | - S Kwak
- University of Tokyo, Tokyo, Japan
| | - C H Selzman
- University of Utah, Salt Lake City, United States of America
| | - M Martini
- Polyclinic Agostino Gemelli, Rome, Italy
| | - S Dimmeler
- Wolfgang Goethe University, Frankfurt am Main, Germany
| | - A Gallo
- Bambino Gesu Children's Hospital, Rome, Italy
| | - S Drakos
- University of Utah, Salt Lake City, United States of America
| | - O Soehnlein
- Institute for Cardiovascular Prevention (IPEK), Munich, Germany
| | - K Stellos
- Newcastle University, Newcastle upon Tyne, United Kingdom
| |
Collapse
|
11
|
Denisov SS, Ippel JH, Heinzmann ACA, Koenen RR, Ortega-Gomez A, Soehnlein O, Hackeng TM, Dijkgraaf I. Tick saliva protein Evasin-3 modulates chemotaxis by disrupting CXCL8 interactions with glycosaminoglycans and CXCR2. J Biol Chem 2019; 294:12370-12379. [PMID: 31235521 PMCID: PMC6699855 DOI: 10.1074/jbc.ra119.008902] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2019] [Revised: 06/11/2019] [Indexed: 01/22/2023] Open
Abstract
Chemokines are a group of chemotaxis proteins that regulate cell trafficking and play important roles in immune responses and inflammation. Ticks are blood-sucking parasites that secrete numerous immune-modulatory agents in their saliva to evade host immune responses. Evasin-3 is a small salivary protein that belongs to a class of chemokine-binding proteins isolated from the brown dog tick, Rhipicephalus sanguineus. Evasin-3 has been shown to have a high affinity for chemokines CXCL1 and CXCL8 and to diminish inflammation in mice. In the present study, solution NMR spectroscopy was used to investigate the structure of Evasin-3 and its CXCL8–Evasin-3 complex. Evasin-3 is found to disrupt the glycosaminoglycan-binding site of CXCL8 and inhibit the interaction of CXCL8 with CXCR2. Structural data were used to design two novel CXCL8-binding peptides. The linear tEv3 17–56 and cyclic tcEv3 16–56 dPG Evasin-3 variants were chemically synthesized by solid-phase peptide synthesis. The affinity of these newly synthesized variants to CXCL8 was measured by surface plasmon resonance biosensor analysis. The Kd values of tEv3 17–56 and tcEv3 16–56 dPG were 27 and 13 nm, respectively. Both compounds effectively inhibited CXCL8-induced migration of polymorphonuclear neutrophils. The present results suggest utility of synthetic Evasin-3 variants as scaffolds for designing and fine-tuning new chemokine-binding agents that suppress immune responses and inflammation.
Collapse
Affiliation(s)
- Stepan S Denisov
- Department of Biochemistry, University of Maastricht, Cardiovascular Research Institute Maastricht, 6229 ER, Maastricht, The Netherlands
| | - Johannes H Ippel
- Department of Biochemistry, University of Maastricht, Cardiovascular Research Institute Maastricht, 6229 ER, Maastricht, The Netherlands
| | - Alexandra C A Heinzmann
- Department of Biochemistry, University of Maastricht, Cardiovascular Research Institute Maastricht, 6229 ER, Maastricht, The Netherlands
| | - Rory R Koenen
- Department of Biochemistry, University of Maastricht, Cardiovascular Research Institute Maastricht, 6229 ER, Maastricht, The Netherlands
| | - Almudena Ortega-Gomez
- Institute for Cardiovascular Prevention, Ludwig Maximilian University, 80336, Munich, Germany
| | - Oliver Soehnlein
- Institute for Cardiovascular Prevention, Ludwig Maximilian University, 80336, Munich, Germany; German Center for Cardiovascular Research, 13316, Berlin, Germany; Partner Site Munich Heart Alliance, 80802 Munich, Germany; Department of Physiology and Pharmacology and Department of Medicine, Karolinska Institutet, SE-171 77 Stockholm, Sweden
| | - Tilman M Hackeng
- Department of Biochemistry, University of Maastricht, Cardiovascular Research Institute Maastricht, 6229 ER, Maastricht, The Netherlands
| | - Ingrid Dijkgraaf
- Department of Biochemistry, University of Maastricht, Cardiovascular Research Institute Maastricht, 6229 ER, Maastricht, The Netherlands.
| |
Collapse
|
12
|
Gatsiou A, Soehnlein O, Garcia-Gonzalez C, Ortega-Gomez A, Kwak S, Selzman CH, Braun T, Drakos S, Dimmeler S, Stellos K. 27The RNA editor ADAR2 links inflammation to functional recovery from ischemic diseases. Cardiovasc Res 2018. [DOI: 10.1093/cvr/cvy060.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- A Gatsiou
- JW Goethe University, Institute of Cardiovascular Regeneration, Frankfurt am Main, Germany
| | - O Soehnlein
- Institute for Cardiovascular Prevention (IPEK), Munich, Germany
| | - C Garcia-Gonzalez
- Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
| | - A Ortega-Gomez
- Institute for Cardiovascular Prevention (IPEK), Munich, Germany
| | - S Kwak
- University of Tokyo, Tokyo, Japan
| | - C H Selzman
- University of Utah, Utah, United States of America
| | - T Braun
- Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
| | - S Drakos
- University of Utah, Utah, United States of America
| | - S Dimmeler
- JW Goethe University, Institute of Cardiovascular Regeneration, Frankfurt am Main, Germany
| | - K Stellos
- JW Goethe University, Institute of Cardiovascular Regeneration, Frankfurt am Main, Germany
| |
Collapse
|
13
|
von Hundelshausen P, Agten SM, Eckardt V, Blanchet X, Schmitt MM, Ippel H, Neideck C, Bidzhekov K, Leberzammer J, Wichapong K, Faussner A, Drechsler M, Grommes J, van Geffen JP, Li H, Ortega-Gomez A, Megens RTA, Naumann R, Dijkgraaf I, Nicolaes GAF, Döring Y, Soehnlein O, Lutgens E, Heemskerk JWM, Koenen RR, Mayo KH, Hackeng TM, Weber C. Chemokine interactome mapping enables tailored intervention in acute and chronic inflammation. Sci Transl Med 2017; 9:9/384/eaah6650. [PMID: 28381538 DOI: 10.1126/scitranslmed.aah6650] [Citation(s) in RCA: 80] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2016] [Revised: 01/18/2017] [Accepted: 03/01/2017] [Indexed: 12/21/2022]
Abstract
Chemokines orchestrate leukocyte trafficking and function in health and disease. Heterophilic interactions between chemokines in a given microenvironment may amplify, inhibit, or modulate their activity; however, a systematic evaluation of the chemokine interactome has not been performed. We used immunoligand blotting and surface plasmon resonance to obtain a comprehensive map of chemokine-chemokine interactions and to confirm their specificity. Structure-function analyses revealed that chemokine activity can be enhanced by CC-type heterodimers but inhibited by CXC-type heterodimers. Functional synergism was achieved through receptor heteromerization induced by CCL5-CCL17 or receptor retention at the cell surface via auxiliary proteoglycan binding of CCL5-CXCL4. In contrast, inhibitory activity relied on conformational changes (in CXCL12), affecting receptor signaling. Obligate CC-type heterodimers showed high efficacy and potency and drove acute lung injury and atherosclerosis, processes abrogated by specific CCL5-derived peptide inhibitors or knock-in of an interaction-deficient CXCL4 variant. Atheroprotective effects of CCL17 deficiency were phenocopied by a CCL5-derived peptide disrupting CCL5-CCL17 heterodimers, whereas a CCL5 α-helix peptide mimicked inhibitory effects on CXCL12-driven platelet aggregation. Thus, formation of specific chemokine heterodimers differentially dictates functional activity and can be exploited for therapeutic targeting.
Collapse
Affiliation(s)
- Philipp von Hundelshausen
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität München, Munich, Germany.,German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany
| | - Stijn M Agten
- Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands
| | - Veit Eckardt
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität München, Munich, Germany
| | - Xavier Blanchet
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität München, Munich, Germany
| | - Martin M Schmitt
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität München, Munich, Germany
| | - Hans Ippel
- Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands
| | - Carlos Neideck
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität München, Munich, Germany
| | - Kiril Bidzhekov
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität München, Munich, Germany
| | - Julian Leberzammer
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität München, Munich, Germany
| | - Kanin Wichapong
- Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands
| | - Alexander Faussner
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität München, Munich, Germany
| | - Maik Drechsler
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität München, Munich, Germany
| | - Jochen Grommes
- Department of Vascular Surgery, RWTH Aachen University, Aachen, Germany
| | - Johanna P van Geffen
- Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands
| | - He Li
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität München, Munich, Germany
| | - Almudena Ortega-Gomez
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität München, Munich, Germany
| | - Remco T A Megens
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität München, Munich, Germany
| | - Ronald Naumann
- Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
| | - Ingrid Dijkgraaf
- Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands
| | - Gerry A F Nicolaes
- Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands
| | - Yvonne Döring
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität München, Munich, Germany.,German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany
| | - Oliver Soehnlein
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität München, Munich, Germany.,German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany.,Department of Physiology and Pharmacology, Karolinksa Institutet, Stockholm, Sweden
| | - Esther Lutgens
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität München, Munich, Germany.,German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany.,Department of Medical Biochemistry, AMC, Amsterdam, Netherlands
| | - Johan W M Heemskerk
- German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany
| | - Rory R Koenen
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität München, Munich, Germany.,Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands
| | - Kevin H Mayo
- Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands.,Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA
| | - Tilman M Hackeng
- Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands
| | - Christian Weber
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität München, Munich, Germany. .,German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany.,Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands
| |
Collapse
|
14
|
van der Vorst EPC, Maas SL, Ortega-Gomez A, Hameleers JMM, Bianchini M, Asare Y, Soehnlein O, Döring Y, Weber C, Megens RTA. Functional ex-vivo Imaging of Arterial Cellular Recruitment and Lipid Extravasation. Bio Protoc 2017; 7:e2344. [PMID: 28890907 DOI: 10.21769/bioprotoc.2344] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022] Open
Abstract
The main purpose of this sophisticated and highly versatile method is to visualize and quantify structural vessel wall properties, cellular recruitment, and lipid/dextran extravasation under physiological conditions in living arteries. This will be of interest for a broad range of researchers within the field of inflammation, hypertension, atherosclerosis, and even the pharmaceutical industry. Currently, many researchers are using in vitro techniques to evaluate cellular recruitment, like transwell or flow chamber systems with cultured cells, with unclear physiological comparability. The here introduced method describes in detail the use of a sophisticated and flexible method to study arterial wall properties and leukocyte recruitment in fresh and viable murine carotid arteries ex vivo under arterial flow conditions. This model mimics the in vivo situation and allows the use of cells and arteries isolated from two different donors (for example, wildtype vs. specific knockouts) to be combined into one experiments, thereby providing information on both leukocyte and/or endothelial cell properties of both donors. As such, this model can be considered an alternative for the complicated and invasive in vivo studies, such as parabiotic experiments.
Collapse
Affiliation(s)
- Emiel P C van der Vorst
- Institute for Cardiovascular Prevention (IPEK), Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany
| | - Sanne L Maas
- Institute for Cardiovascular Prevention (IPEK), Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany
| | - Almudena Ortega-Gomez
- Institute for Cardiovascular Prevention (IPEK), Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany
| | - Jeroen M M Hameleers
- Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands
| | - Mariaelvy Bianchini
- Institute for Cardiovascular Prevention (IPEK), Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany
| | - Yaw Asare
- Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany
| | - Oliver Soehnlein
- Institute for Cardiovascular Prevention (IPEK), Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany.,DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany.,Department of Physiology and Pharmacology (FyFa), Karolinska Institutet, Stockholm, Sweden
| | - Yvonne Döring
- Institute for Cardiovascular Prevention (IPEK), Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany
| | - Christian Weber
- Institute for Cardiovascular Prevention (IPEK), Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany.,Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands.,DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany
| | - Remco T A Megens
- Institute for Cardiovascular Prevention (IPEK), Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany.,Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands
| |
Collapse
|
15
|
Ortega-Gomez A, Salvermoser M, Rossaint J, Pick R, Brauner J, Lemnitzer P, Tilgner J, de Jong RJ, Megens RTA, Jamasbi J, Döring Y, Pham CT, Scheiermann C, Siess W, Drechsler M, Weber C, Grommes J, Zarbock A, Walzog B, Soehnlein O. Cathepsin G Controls Arterial But Not Venular Myeloid Cell Recruitment. Circulation 2016; 134:1176-1188. [PMID: 27660294 DOI: 10.1161/circulationaha.116.024790] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/23/2016] [Accepted: 08/31/2016] [Indexed: 12/30/2022]
Abstract
BACKGROUND Therapeutic targeting of arterial leukocyte recruitment in the context of atherosclerosis has been disappointing in clinical studies. Reasons for such failures include the lack of knowledge of arterial-specific recruitment patterns. Here we establish the importance of the cathepsin G (CatG) in the context of arterial myeloid cell recruitment. METHODS Intravital microscopy of the carotid artery, the jugular vein, and cremasteric arterioles and venules in Apoe-/-and CatG-deficient mice (Apoe-/-Ctsg-/-) was used to study site-specific myeloid cell behavior after high-fat diet feeding or tumor necrosis factor stimulation. Atherosclerosis development was assessed in aortic root sections after 4 weeks of high-fat diet, whereas lung inflammation was assessed after inhalation of lipopolysaccharide. Endothelial deposition of CatG and CCL5 was quantified in whole-mount preparations using 2-photon and confocal microscopy. RESULTS Our observations elucidated a crucial role for CatG during arterial leukocyte adhesion, an effect not found during venular adhesion. Consequently, CatG deficiency attenuates atherosclerosis but not acute lung inflammation. Mechanistically, CatG is immobilized on arterial endothelium where it activates leukocytes to firmly adhere engaging integrin clustering, a process of crucial importance to achieve effective adherence under high-shear flow. Therapeutic neutralization of CatG specifically abrogated arterial leukocyte adhesion without affecting myeloid cell adhesion in the microcirculation. Repetitive application of CatG-neutralizing antibodies permitted inhibition of atherogenesis in mice. CONCLUSIONS Taken together, these findings present evidence of an arterial-specific recruitment pattern centered on CatG-instructed adhesion strengthening. The inhibition of this process could provide a novel strategy for treatment of arterial inflammation with limited side effects.
Collapse
Affiliation(s)
- Almudena Ortega-Gomez
- From IPEK, LMU Munich, Germany (A.O.-G., J.B., P.L., R.d.J., R.T.A.M., J.J., Y.D., W.S., M.D., C.W., J.G., O.S.); WBex, LMU Munich, Germany (M.S., R.P., C.S., B.W.); Department of Anaesthesiology, University Münster, Germany (J.R., A.Z.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.T., J.G.); CARIM, Maastricht University, the Netherlands (R.T.A.M., C.W.); DZHK, partner site Munich Heart Alliance, Germany (Y.D., M.D., C.W., O.S.); Department of Medicine, Washington University, St Louis, MO (C.T.P.); and AMC, Department of Pathology, Amsterdam University, the Netherlands (M.D., O.S.)
| | - Melanie Salvermoser
- From IPEK, LMU Munich, Germany (A.O.-G., J.B., P.L., R.d.J., R.T.A.M., J.J., Y.D., W.S., M.D., C.W., J.G., O.S.); WBex, LMU Munich, Germany (M.S., R.P., C.S., B.W.); Department of Anaesthesiology, University Münster, Germany (J.R., A.Z.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.T., J.G.); CARIM, Maastricht University, the Netherlands (R.T.A.M., C.W.); DZHK, partner site Munich Heart Alliance, Germany (Y.D., M.D., C.W., O.S.); Department of Medicine, Washington University, St Louis, MO (C.T.P.); and AMC, Department of Pathology, Amsterdam University, the Netherlands (M.D., O.S.)
| | - Jan Rossaint
- From IPEK, LMU Munich, Germany (A.O.-G., J.B., P.L., R.d.J., R.T.A.M., J.J., Y.D., W.S., M.D., C.W., J.G., O.S.); WBex, LMU Munich, Germany (M.S., R.P., C.S., B.W.); Department of Anaesthesiology, University Münster, Germany (J.R., A.Z.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.T., J.G.); CARIM, Maastricht University, the Netherlands (R.T.A.M., C.W.); DZHK, partner site Munich Heart Alliance, Germany (Y.D., M.D., C.W., O.S.); Department of Medicine, Washington University, St Louis, MO (C.T.P.); and AMC, Department of Pathology, Amsterdam University, the Netherlands (M.D., O.S.)
| | - Robert Pick
- From IPEK, LMU Munich, Germany (A.O.-G., J.B., P.L., R.d.J., R.T.A.M., J.J., Y.D., W.S., M.D., C.W., J.G., O.S.); WBex, LMU Munich, Germany (M.S., R.P., C.S., B.W.); Department of Anaesthesiology, University Münster, Germany (J.R., A.Z.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.T., J.G.); CARIM, Maastricht University, the Netherlands (R.T.A.M., C.W.); DZHK, partner site Munich Heart Alliance, Germany (Y.D., M.D., C.W., O.S.); Department of Medicine, Washington University, St Louis, MO (C.T.P.); and AMC, Department of Pathology, Amsterdam University, the Netherlands (M.D., O.S.)
| | - Janine Brauner
- From IPEK, LMU Munich, Germany (A.O.-G., J.B., P.L., R.d.J., R.T.A.M., J.J., Y.D., W.S., M.D., C.W., J.G., O.S.); WBex, LMU Munich, Germany (M.S., R.P., C.S., B.W.); Department of Anaesthesiology, University Münster, Germany (J.R., A.Z.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.T., J.G.); CARIM, Maastricht University, the Netherlands (R.T.A.M., C.W.); DZHK, partner site Munich Heart Alliance, Germany (Y.D., M.D., C.W., O.S.); Department of Medicine, Washington University, St Louis, MO (C.T.P.); and AMC, Department of Pathology, Amsterdam University, the Netherlands (M.D., O.S.)
| | - Patricia Lemnitzer
- From IPEK, LMU Munich, Germany (A.O.-G., J.B., P.L., R.d.J., R.T.A.M., J.J., Y.D., W.S., M.D., C.W., J.G., O.S.); WBex, LMU Munich, Germany (M.S., R.P., C.S., B.W.); Department of Anaesthesiology, University Münster, Germany (J.R., A.Z.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.T., J.G.); CARIM, Maastricht University, the Netherlands (R.T.A.M., C.W.); DZHK, partner site Munich Heart Alliance, Germany (Y.D., M.D., C.W., O.S.); Department of Medicine, Washington University, St Louis, MO (C.T.P.); and AMC, Department of Pathology, Amsterdam University, the Netherlands (M.D., O.S.)
| | - Jessica Tilgner
- From IPEK, LMU Munich, Germany (A.O.-G., J.B., P.L., R.d.J., R.T.A.M., J.J., Y.D., W.S., M.D., C.W., J.G., O.S.); WBex, LMU Munich, Germany (M.S., R.P., C.S., B.W.); Department of Anaesthesiology, University Münster, Germany (J.R., A.Z.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.T., J.G.); CARIM, Maastricht University, the Netherlands (R.T.A.M., C.W.); DZHK, partner site Munich Heart Alliance, Germany (Y.D., M.D., C.W., O.S.); Department of Medicine, Washington University, St Louis, MO (C.T.P.); and AMC, Department of Pathology, Amsterdam University, the Netherlands (M.D., O.S.)
| | - Renske J de Jong
- From IPEK, LMU Munich, Germany (A.O.-G., J.B., P.L., R.d.J., R.T.A.M., J.J., Y.D., W.S., M.D., C.W., J.G., O.S.); WBex, LMU Munich, Germany (M.S., R.P., C.S., B.W.); Department of Anaesthesiology, University Münster, Germany (J.R., A.Z.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.T., J.G.); CARIM, Maastricht University, the Netherlands (R.T.A.M., C.W.); DZHK, partner site Munich Heart Alliance, Germany (Y.D., M.D., C.W., O.S.); Department of Medicine, Washington University, St Louis, MO (C.T.P.); and AMC, Department of Pathology, Amsterdam University, the Netherlands (M.D., O.S.)
| | - Remco T A Megens
- From IPEK, LMU Munich, Germany (A.O.-G., J.B., P.L., R.d.J., R.T.A.M., J.J., Y.D., W.S., M.D., C.W., J.G., O.S.); WBex, LMU Munich, Germany (M.S., R.P., C.S., B.W.); Department of Anaesthesiology, University Münster, Germany (J.R., A.Z.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.T., J.G.); CARIM, Maastricht University, the Netherlands (R.T.A.M., C.W.); DZHK, partner site Munich Heart Alliance, Germany (Y.D., M.D., C.W., O.S.); Department of Medicine, Washington University, St Louis, MO (C.T.P.); and AMC, Department of Pathology, Amsterdam University, the Netherlands (M.D., O.S.)
| | - Janina Jamasbi
- From IPEK, LMU Munich, Germany (A.O.-G., J.B., P.L., R.d.J., R.T.A.M., J.J., Y.D., W.S., M.D., C.W., J.G., O.S.); WBex, LMU Munich, Germany (M.S., R.P., C.S., B.W.); Department of Anaesthesiology, University Münster, Germany (J.R., A.Z.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.T., J.G.); CARIM, Maastricht University, the Netherlands (R.T.A.M., C.W.); DZHK, partner site Munich Heart Alliance, Germany (Y.D., M.D., C.W., O.S.); Department of Medicine, Washington University, St Louis, MO (C.T.P.); and AMC, Department of Pathology, Amsterdam University, the Netherlands (M.D., O.S.)
| | - Yvonne Döring
- From IPEK, LMU Munich, Germany (A.O.-G., J.B., P.L., R.d.J., R.T.A.M., J.J., Y.D., W.S., M.D., C.W., J.G., O.S.); WBex, LMU Munich, Germany (M.S., R.P., C.S., B.W.); Department of Anaesthesiology, University Münster, Germany (J.R., A.Z.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.T., J.G.); CARIM, Maastricht University, the Netherlands (R.T.A.M., C.W.); DZHK, partner site Munich Heart Alliance, Germany (Y.D., M.D., C.W., O.S.); Department of Medicine, Washington University, St Louis, MO (C.T.P.); and AMC, Department of Pathology, Amsterdam University, the Netherlands (M.D., O.S.)
| | - Christine T Pham
- From IPEK, LMU Munich, Germany (A.O.-G., J.B., P.L., R.d.J., R.T.A.M., J.J., Y.D., W.S., M.D., C.W., J.G., O.S.); WBex, LMU Munich, Germany (M.S., R.P., C.S., B.W.); Department of Anaesthesiology, University Münster, Germany (J.R., A.Z.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.T., J.G.); CARIM, Maastricht University, the Netherlands (R.T.A.M., C.W.); DZHK, partner site Munich Heart Alliance, Germany (Y.D., M.D., C.W., O.S.); Department of Medicine, Washington University, St Louis, MO (C.T.P.); and AMC, Department of Pathology, Amsterdam University, the Netherlands (M.D., O.S.)
| | - Christoph Scheiermann
- From IPEK, LMU Munich, Germany (A.O.-G., J.B., P.L., R.d.J., R.T.A.M., J.J., Y.D., W.S., M.D., C.W., J.G., O.S.); WBex, LMU Munich, Germany (M.S., R.P., C.S., B.W.); Department of Anaesthesiology, University Münster, Germany (J.R., A.Z.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.T., J.G.); CARIM, Maastricht University, the Netherlands (R.T.A.M., C.W.); DZHK, partner site Munich Heart Alliance, Germany (Y.D., M.D., C.W., O.S.); Department of Medicine, Washington University, St Louis, MO (C.T.P.); and AMC, Department of Pathology, Amsterdam University, the Netherlands (M.D., O.S.)
| | - Wolfgang Siess
- From IPEK, LMU Munich, Germany (A.O.-G., J.B., P.L., R.d.J., R.T.A.M., J.J., Y.D., W.S., M.D., C.W., J.G., O.S.); WBex, LMU Munich, Germany (M.S., R.P., C.S., B.W.); Department of Anaesthesiology, University Münster, Germany (J.R., A.Z.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.T., J.G.); CARIM, Maastricht University, the Netherlands (R.T.A.M., C.W.); DZHK, partner site Munich Heart Alliance, Germany (Y.D., M.D., C.W., O.S.); Department of Medicine, Washington University, St Louis, MO (C.T.P.); and AMC, Department of Pathology, Amsterdam University, the Netherlands (M.D., O.S.)
| | - Maik Drechsler
- From IPEK, LMU Munich, Germany (A.O.-G., J.B., P.L., R.d.J., R.T.A.M., J.J., Y.D., W.S., M.D., C.W., J.G., O.S.); WBex, LMU Munich, Germany (M.S., R.P., C.S., B.W.); Department of Anaesthesiology, University Münster, Germany (J.R., A.Z.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.T., J.G.); CARIM, Maastricht University, the Netherlands (R.T.A.M., C.W.); DZHK, partner site Munich Heart Alliance, Germany (Y.D., M.D., C.W., O.S.); Department of Medicine, Washington University, St Louis, MO (C.T.P.); and AMC, Department of Pathology, Amsterdam University, the Netherlands (M.D., O.S.)
| | - Christian Weber
- From IPEK, LMU Munich, Germany (A.O.-G., J.B., P.L., R.d.J., R.T.A.M., J.J., Y.D., W.S., M.D., C.W., J.G., O.S.); WBex, LMU Munich, Germany (M.S., R.P., C.S., B.W.); Department of Anaesthesiology, University Münster, Germany (J.R., A.Z.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.T., J.G.); CARIM, Maastricht University, the Netherlands (R.T.A.M., C.W.); DZHK, partner site Munich Heart Alliance, Germany (Y.D., M.D., C.W., O.S.); Department of Medicine, Washington University, St Louis, MO (C.T.P.); and AMC, Department of Pathology, Amsterdam University, the Netherlands (M.D., O.S.)
| | - Jochen Grommes
- From IPEK, LMU Munich, Germany (A.O.-G., J.B., P.L., R.d.J., R.T.A.M., J.J., Y.D., W.S., M.D., C.W., J.G., O.S.); WBex, LMU Munich, Germany (M.S., R.P., C.S., B.W.); Department of Anaesthesiology, University Münster, Germany (J.R., A.Z.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.T., J.G.); CARIM, Maastricht University, the Netherlands (R.T.A.M., C.W.); DZHK, partner site Munich Heart Alliance, Germany (Y.D., M.D., C.W., O.S.); Department of Medicine, Washington University, St Louis, MO (C.T.P.); and AMC, Department of Pathology, Amsterdam University, the Netherlands (M.D., O.S.)
| | - Alexander Zarbock
- From IPEK, LMU Munich, Germany (A.O.-G., J.B., P.L., R.d.J., R.T.A.M., J.J., Y.D., W.S., M.D., C.W., J.G., O.S.); WBex, LMU Munich, Germany (M.S., R.P., C.S., B.W.); Department of Anaesthesiology, University Münster, Germany (J.R., A.Z.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.T., J.G.); CARIM, Maastricht University, the Netherlands (R.T.A.M., C.W.); DZHK, partner site Munich Heart Alliance, Germany (Y.D., M.D., C.W., O.S.); Department of Medicine, Washington University, St Louis, MO (C.T.P.); and AMC, Department of Pathology, Amsterdam University, the Netherlands (M.D., O.S.)
| | - Barbara Walzog
- From IPEK, LMU Munich, Germany (A.O.-G., J.B., P.L., R.d.J., R.T.A.M., J.J., Y.D., W.S., M.D., C.W., J.G., O.S.); WBex, LMU Munich, Germany (M.S., R.P., C.S., B.W.); Department of Anaesthesiology, University Münster, Germany (J.R., A.Z.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.T., J.G.); CARIM, Maastricht University, the Netherlands (R.T.A.M., C.W.); DZHK, partner site Munich Heart Alliance, Germany (Y.D., M.D., C.W., O.S.); Department of Medicine, Washington University, St Louis, MO (C.T.P.); and AMC, Department of Pathology, Amsterdam University, the Netherlands (M.D., O.S.)
| | - Oliver Soehnlein
- From IPEK, LMU Munich, Germany (A.O.-G., J.B., P.L., R.d.J., R.T.A.M., J.J., Y.D., W.S., M.D., C.W., J.G., O.S.); WBex, LMU Munich, Germany (M.S., R.P., C.S., B.W.); Department of Anaesthesiology, University Münster, Germany (J.R., A.Z.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Germany (J.T., J.G.); CARIM, Maastricht University, the Netherlands (R.T.A.M., C.W.); DZHK, partner site Munich Heart Alliance, Germany (Y.D., M.D., C.W., O.S.); Department of Medicine, Washington University, St Louis, MO (C.T.P.); and AMC, Department of Pathology, Amsterdam University, the Netherlands (M.D., O.S.).
| |
Collapse
|
16
|
Alard JE, Ortega-Gomez A, Wichapong K, Bongiovanni D, Horckmans M, Megens RTA, Leoni G, Ferraro B, Rossaint J, Paulin N, Ng J, Ippel H, Suylen D, Hinkel R, Blanchet X, Gaillard F, D'Amico M, von Hundelshausen P, Zarbock A, Scheiermann C, Hackeng TM, Steffens S, Kupatt C, Nicolaes GAF, Weber C, Soehnlein O. Recruitment of classical monocytes can be inhibited by disturbing heteromers of neutrophil HNP1 and platelet CCL5. Sci Transl Med 2016; 7:317ra196. [PMID: 26659570 DOI: 10.1126/scitranslmed.aad5330] [Citation(s) in RCA: 79] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
In acute and chronic inflammation, neutrophils and platelets, both of which promote monocyte recruitment, are often activated simultaneously. We investigated how secretory products of neutrophils and platelets synergize to enhance the recruitment of monocytes. We found that neutrophil-borne human neutrophil peptide 1 (HNP1, α-defensin) and platelet-derived CCL5 form heteromers. These heteromers stimulate monocyte adhesion through CCR5 ligation. We further determined structural features of HNP1-CCL5 heteromers and designed a stable peptide that could disturb proinflammatory HNP1-CCL5 interactions. This peptide attenuated monocyte and macrophage recruitment in a mouse model of myocardial infarction. These results establish the in vivo relevance of heteromers formed between proteins released from neutrophils and platelets and show the potential of targeting heteromer formation to resolve acute or chronic inflammation.
Collapse
Affiliation(s)
- Jean-Eric Alard
- Institute for Cardiovascular Prevention, Ludwig Maximilians University Munich, 80336 Munich, Germany
| | - Almudena Ortega-Gomez
- Institute for Cardiovascular Prevention, Ludwig Maximilians University Munich, 80336 Munich, Germany
| | - Kanin Wichapong
- Department of Biochemistry, Cardiovascular Research Institute Maastricht, University Maastricht, 6200 Maastricht, Netherlands
| | - Dario Bongiovanni
- Medizinische Klinik I, Technische Universität München, 81675 Munich, Germany
| | - Michael Horckmans
- Institute for Cardiovascular Prevention, Ludwig Maximilians University Munich, 80336 Munich, Germany
| | - Remco T A Megens
- Institute for Cardiovascular Prevention, Ludwig Maximilians University Munich, 80336 Munich, Germany. Department of Biochemistry, Cardiovascular Research Institute Maastricht, University Maastricht, 6200 Maastricht, Netherlands
| | - Giovanna Leoni
- Institute for Cardiovascular Prevention, Ludwig Maximilians University Munich, 80336 Munich, Germany
| | - Bartolo Ferraro
- Institute for Cardiovascular Prevention, Ludwig Maximilians University Munich, 80336 Munich, Germany. Department of Experimental Medicine, University of Naples, 80138 Naples, Italy
| | - Jan Rossaint
- Department of Anesthesiology, University of Münster, 48149 Münster, Germany
| | - Nicole Paulin
- Institute for Cardiovascular Prevention, Ludwig Maximilians University Munich, 80336 Munich, Germany
| | - Judy Ng
- Medizinische Klinik I, Technische Universität München, 81675 Munich, Germany
| | - Hans Ippel
- Department of Biochemistry, Cardiovascular Research Institute Maastricht, University Maastricht, 6200 Maastricht, Netherlands
| | - Dennis Suylen
- Department of Biochemistry, Cardiovascular Research Institute Maastricht, University Maastricht, 6200 Maastricht, Netherlands
| | - Rabea Hinkel
- Institute for Cardiovascular Prevention, Ludwig Maximilians University Munich, 80336 Munich, Germany. Medizinische Klinik I, Technische Universität München, 81675 Munich, Germany. German Centre for Cardiovascular Research, partner site Munich Heart Alliance, 80336 Munich, Germany
| | - Xavier Blanchet
- Institute for Cardiovascular Prevention, Ludwig Maximilians University Munich, 80336 Munich, Germany
| | - Fanny Gaillard
- Roscoff Biological Station, Pierre et Marie Curie University, 29682 Paris, France
| | - Michele D'Amico
- Department of Experimental Medicine, University of Naples, 80138 Naples, Italy
| | | | - Alexander Zarbock
- Department of Anesthesiology, University of Münster, 48149 Münster, Germany
| | - Christoph Scheiermann
- Walter-Brendel-Center of Experimental Medicine, Ludwig Maximilians University Munich, 81377 Munich, Germany
| | - Tilman M Hackeng
- Department of Biochemistry, Cardiovascular Research Institute Maastricht, University Maastricht, 6200 Maastricht, Netherlands
| | - Sabine Steffens
- Institute for Cardiovascular Prevention, Ludwig Maximilians University Munich, 80336 Munich, Germany. German Centre for Cardiovascular Research, partner site Munich Heart Alliance, 80336 Munich, Germany
| | - Christian Kupatt
- Medizinische Klinik I, Technische Universität München, 81675 Munich, Germany. German Centre for Cardiovascular Research, partner site Munich Heart Alliance, 80336 Munich, Germany
| | - Gerry A F Nicolaes
- Department of Biochemistry, Cardiovascular Research Institute Maastricht, University Maastricht, 6200 Maastricht, Netherlands
| | - Christian Weber
- Institute for Cardiovascular Prevention, Ludwig Maximilians University Munich, 80336 Munich, Germany. Department of Biochemistry, Cardiovascular Research Institute Maastricht, University Maastricht, 6200 Maastricht, Netherlands. German Centre for Cardiovascular Research, partner site Munich Heart Alliance, 80336 Munich, Germany
| | - Oliver Soehnlein
- Institute for Cardiovascular Prevention, Ludwig Maximilians University Munich, 80336 Munich, Germany. German Centre for Cardiovascular Research, partner site Munich Heart Alliance, 80336 Munich, Germany. Department of Pathology, Academic Medical Center, 1105 Amsterdam, Netherlands.
| |
Collapse
|
17
|
Wichapong K, Alard JE, Ortega-Gomez A, Weber C, Hackeng TM, Soehnlein O, Nicolaes GAF. Structure-Based Design of Peptidic Inhibitors of the Interaction between CC Chemokine Ligand 5 (CCL5) and Human Neutrophil Peptides 1 (HNP1). J Med Chem 2016; 59:4289-301. [PMID: 26871718 DOI: 10.1021/acs.jmedchem.5b01952] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Protein-protein interactions (PPIs) are receiving increasing interest, much sparked by the realization that they represent druggable targets. Recently, we successfully developed a peptidic inhibitor, RRYGTSKYQ ("SKY" peptide), that shows high potential in vitro and in vivo to interrupt a PPI between the platelet-borne chemokine CCL5 and the neutrophil-derived granule protein HNP1. This PPI plays a vital role in monocyte adhesion, representing a key mechanism in acute and chronic inflammatory diseases. Here, we present extensive and detailed computational methods applied to develop the SKY peptide. We combined experimentally determined binding affinities (KD) of several orthologs of CCL5 with HNP1 with in silico studies to identify the most likely heterodimeric CCL5-HNP1 complex which was subsequently used as a starting structure to rationally design peptidic inhibitors. Our method represents a fast and simple approach that can be widely applied to determine other protein-protein complexes and moreover to design inhibitors or stabilizers of protein-protein interaction.
Collapse
Affiliation(s)
- Kanin Wichapong
- Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University , 6200 MD Maastricht, The Netherlands
| | - Jean-Eric Alard
- Institute for Cardiovascular Prevention, Ludwig Maximilians University Munich , 80336 Munich, Germany
| | - Almudena Ortega-Gomez
- Institute for Cardiovascular Prevention, Ludwig Maximilians University Munich , 80336 Munich, Germany
| | - Christian Weber
- Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University , 6200 MD Maastricht, The Netherlands.,Institute for Cardiovascular Prevention, Ludwig Maximilians University Munich , 80336 Munich, Germany.,German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, 80336 Munich, Germany
| | - Tilman M Hackeng
- Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University , 6200 MD Maastricht, The Netherlands
| | - Oliver Soehnlein
- Institute for Cardiovascular Prevention, Ludwig Maximilians University Munich , 80336 Munich, Germany.,German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, 80336 Munich, Germany.,Department of Pathology, Academic Medical Center (AMC), University of Amsterdam , 1105 AZ Amsterdam, The Netherlands
| | - Gerry A F Nicolaes
- Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University , 6200 MD Maastricht, The Netherlands
| |
Collapse
|
18
|
Bermudez B, Ortega-Gomez A, Varela LM, Villar J, Abia R, Muriana FJG, Lopez S. Clustering effects on postprandial insulin secretion and sensitivity in response to meals with different fatty acid compositions. Food Funct 2015; 5:1374-80. [PMID: 24752559 DOI: 10.1039/c4fo00067f] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Dietary fatty acids play a role in glucose homeostasis. The aim of this study was to assess the individual relationship between dietary saturated (SFA), monounsaturated (MUFA) and polyunsaturated (PUFA) fatty acids with postprandial β-cell function and insulin sensitivity in subjects with normal and high fasting triglycerides. We assessed postprandial β-cell function (by the insulinogenic index and the ratio of the insulin to glucose areas under the time-concentration curve) and insulin sensitivity (by the oral glucose and the minimal model insulin sensitivity indices) over four nonconsecutive, randomly assigned, high-fat meals containing a panel of SFA (palmitic and stearic acids), MUFA (palmitoleic and oleic acids) and PUFA (linoleic and α-linolenic acids) in 14 subjects with normal and in 14 subjects with high fasting triglycerides. The proportions of each fatty acid in the meals and the values for surrogate measures of postprandial β-cell function and insulin sensitivity were subjected to a Pearson correlation and hierarchical cluster analysis, which revealed two classes of dietary fatty acids for regulating postprandial glucose homeostasis. We successfully discriminated the adverse effects of SFA palmitic acid from the beneficial effects of MUFA oleic acid on postprandial β-cell function (r ≥ 0.84 for SFA palmitic acid and r ≥ -0.71 for MUFA oleic acid; P < 0.05) and insulin sensitivity (r ≥ -0.92 for SFA palmitic acid and r ≥ 0.89 for MUFA oleic acid; P < 0.001) both in subjects with normal and high fasting triglycerides. In conclusion, dietary MUFA oleic acid, in contrast to SFA palmitic acid, favours the tuning towards better postprandial glycaemic control in subjects with normal and high fasting triglycerides.
Collapse
Affiliation(s)
- Beatriz Bermudez
- Laboratory of Cellular and Molecular Nutrition, Instituto de la Grasa, CSIC, Avda. Padre Garcia Tejero 4, 41012 Seville, Spain.
| | | | | | | | | | | | | |
Collapse
|
19
|
Moreno JA, Ortega-Gomez A, Rubio-Navarro A, Louedec L, Ho-Tin-Noé B, Caligiuri G, Nicoletti A, Levoye A, Plantier L, Meilhac O. High-density lipoproteins potentiate α1-antitrypsin therapy in elastase-induced pulmonary emphysema. Am J Respir Cell Mol Biol 2014; 51:536-49. [PMID: 24787644 DOI: 10.1165/rcmb.2013-0103oc] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Several studies report that high-density lipoproteins (HDLs) can carry α1-antitrypsin (AAT; an elastase inhibitor). We aimed to determine whether injection of exogenous HDL, enriched or not in AAT, may have protective effects against pulmonary emphysema. After tracheal instillation of saline or elastase, mice were randomly treated intravenously with saline, human plasma HDL (75 mg apolipoprotein A1/kg), HDL-AAT (75 mg apolipoprotein A1-3.75 mg AAT/kg), or AAT alone (3.75 mg/kg) at 2, 24, 48, and 72 hours. We have shown that HDL-AAT reached the lung and prevented the development of pulmonary emphysema by 59.3% at 3 weeks (alveoli mean chord length, 22.9 ± 2.8 μm versus 30.7 ± 4.5 μm; P < 0.001), whereas injection of HDL or AAT alone only showed a moderate, nonsignificant protective effect (28.2 ± 4.2 μm versus 30.7 ± 5 μm [P = 0.23] and 27.3 ± 5.66 μm versus 30.71 ± 4.96 μm [P = 0.18], respectively). Indeed, protection by HDL-AAT was significantly higher than that observed with HDL or AAT (P = 0.006 and P = 0.048, respectively). This protective effect was associated (at 6, 24, and 72 h) with: (1) a reduction in neutrophil and macrophage number in the bronchoalveolar lavage fluid; (2) decreased concentrations of IL-6, monocyte chemoattractant protein-1, and TNF-α in both bronchoalveolar lavage fluid and plasma; (3) a reduction in matrix metalloproteinase-2 and matrix metalloproteinase-9 activities; and (4) a reduction in the degradation of fibronectin, a marker of tissue damage. In addition, HDL-AAT reduced acute cigarette smoke-induced inflammatory response. Intravenous HDL-AAT treatment afforded a better protection against elastase-induced pulmonary emphysema than AAT alone, and may represent a significant development for the management of emphysema associated with AAT deficiency.
Collapse
Affiliation(s)
- Juan-Antonio Moreno
- 1 Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR)1148, DHU FIRE (Département Hospitalo-Universitaire Fibrosis, Inflammation, REmodeling in cardiovascular, respiratory and renal diseases), Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Varela LM, Ortega-Gomez A, Lopez S, Abia R, Muriana FJG, Bermudez B. The effects of dietary fatty acids on the postprandial triglyceride-rich lipoprotein/apoB48 receptor axis in human monocyte/macrophage cells. J Nutr Biochem 2014; 24:2031-9. [PMID: 24231096 DOI: 10.1016/j.jnutbio.2013.07.004] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2013] [Revised: 06/10/2013] [Accepted: 07/03/2013] [Indexed: 12/26/2022]
Abstract
Intestinally produced triglyceride-rich lipoproteins (TRL) play an important role in the progression of atherosclerosis. In this study, we investigated the relevance of monounsaturated fatty acid (MUFA) and saturated fatty acid (SFA) in postprandial TRL in affecting the transcriptional activity of the apolipoprotein-B48 receptor (ApoB48R) and its functionality in human monocyte/macrophage cells. Healthy male volunteers were administered four standardized high-fat meals containing butter, high-palmitic sunflower oil, olive oil (ROO) or a mixture of vegetable and fish oils (50 g/m(2) body surface area) to obtain a panel of postprandial TRL with gradual MUFA oleic acid-to-SFA palmitic acid ratios. The increase in this ratio was linearly associated with a decrease of ApoB48R up-regulation and lipid accumulation in THP-1 and primary monocytes. ApoB48R mRNA levels and intracellular triglycerides were also lower in the monocytes from volunteers after the ingestion of the ROO meal when compared to the ingestion of the butter meal. In THP-1 macrophages, the increase in the MUFA oleic acid-to-SFA palmitic acid ratio in the postprandial TRL was linearly correlated with an increase in ApoB48R down-regulation and a decrease in lipid accumulation. We also revealed that the nuclear receptor transcription factors PPARα, PPARβ/δ, and PPARγ and the PPAR-RXR transcriptional complex were involved in sensing the proportion of MUFA oleic acid and SFA palmitic acid, and these were also involved in adjusting the transcriptional activity of ApoB48R. The results of this study support the notion that MUFA-rich dietary fats may prevent excessive lipid accumulation in monocyte/macrophage cells by targeting the postprandial TRL/ApoB48R axis.
Collapse
Affiliation(s)
- Lourdes M Varela
- Laboratory of Cellular and Molecular Nutrition, Instituto de la Grasa (CSIC), 41012 Seville, Spain
| | | | | | | | | | | |
Collapse
|
21
|
Lopez S, Bermudez B, Montserrat-de la Paz S, Jaramillo S, Varela LM, Ortega-Gomez A, Abia R, Muriana FJG. Membrane composition and dynamics: a target of bioactive virgin olive oil constituents. Biochim Biophys Acta 2014; 1838:1638-56. [PMID: 24440426 DOI: 10.1016/j.bbamem.2014.01.007] [Citation(s) in RCA: 95] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/07/2013] [Revised: 01/03/2014] [Accepted: 01/07/2014] [Indexed: 12/26/2022]
Abstract
The endogenous synthesis of lipids, which requires suitable dietary raw materials, is critical for the formation of membrane bilayers. In eukaryotic cells, phospholipids are the predominant membrane lipids and consist of hydrophobic acyl chains attached to a hydrophilic head group. The relative balance between saturated, monounsaturated, and polyunsaturated acyl chains is required for the organization and normal function of membranes. Virgin olive oil is the richest natural dietary source of the monounsaturated lipid oleic acid and is one of the key components of the healthy Mediterranean diet. Virgin olive oil also contains a unique constellation of many other lipophilic and amphipathic constituents whose health benefits are still being discovered. The focus of this review is the latest evidence regarding the impact of oleic acid and the minor constituents of virgin olive oil on the arrangement and behavior of lipid bilayers. We highlight the relevance of these interactions to the potential use of virgin olive oil in preserving the functional properties of membranes to maintain health and in modulating membrane functions that can be altered in several pathologies. This article is part of a Special Issue entitled: Membrane Structure and Function: Relevance in the Cell's Physiology, Pathology and Therapy.
Collapse
Affiliation(s)
- Sergio Lopez
- Laboratory of Cellular and Molecular Nutrition, Instituto de la Grasa, CSIC, 41012 Seville, Spain
| | - Beatriz Bermudez
- Laboratory of Cellular and Molecular Nutrition, Instituto de la Grasa, CSIC, 41012 Seville, Spain
| | | | - Sara Jaramillo
- Laboratory of Phytochemicals and Food Quality, Instituto de la Grasa, CSIC, 41014 Seville, Spain
| | - Lourdes M Varela
- Laboratory of Cellular and Molecular Nutrition, Instituto de la Grasa, CSIC, 41012 Seville, Spain
| | - Almudena Ortega-Gomez
- Laboratory of Cellular and Molecular Nutrition, Instituto de la Grasa, CSIC, 41012 Seville, Spain
| | - Rocio Abia
- Laboratory of Cellular and Molecular Nutrition, Instituto de la Grasa, CSIC, 41012 Seville, Spain
| | - Francisco J G Muriana
- Laboratory of Cellular and Molecular Nutrition, Instituto de la Grasa, CSIC, 41012 Seville, Spain.
| |
Collapse
|